Table 1.
Demographic features of 223 OMG patients
| Variables | n (%) |
|---|---|
| Disease duration (y), median (IQR) | 4 (2–6) |
| Gender | (N = 223) |
| Male | 116 (52.0) |
| Female | 107 (48.0) |
| Age of onset | (N = 223) |
| < 20 y | 110 (49.3) |
| ≥ 20 y | 113 (50.7) |
| Initial symptoms | (N = 223) |
| Unilateral ptosis | 110 (49.3) |
| Bilateral ptosis | 40 (17.9) |
| Diplopia | 10 (4.5) |
| Unilateral ptosis with diplopia | 42 (18.8) |
| Bilateral ptosis with diplopia | 21 (9.4) |
| Neostigmine test | (N = 171) |
| Positive | 163 (95.3) |
| Negative | 8(4.7) |
| Positive rate of RNS test | |
| Facial nerve | 25/84 (29.8) |
| Axillary nerve | 18/76 (23.7) |
| Ulnar nerve | 2/74 (2.7) |
| Thyroid abnormality | (N = 102) |
| Hyperthyroidism | 9 (8.8) |
| Subclinical hyperthyroidism | 4 (3.9) |
| Hypothyroidism | 2 (2.0) |
| Subclinical hypothyroidism | 2 (2.0) |
| Thymus abnormality | (N = 174) |
| Thymoma | 25 (14.4) |
| Thymic hyperplasia | 7 (4.0) |
| Non-degraded thymus | 7 (4.0) |
| Immunosuppressants | (N = 223) |
| Steroids | 159 (71.3%) |
| Azathioprine | 8 (3.6%) |
| Steroids + azathioprine | 53 (23.8%) |
| Steroids + cyclosporine A | 2 (0.9%) |
| Steroids + IVIg | 1 (0.4%) |
Abbreviations: RNS Repetitive nerve stimulation, y Year, IQR Interquartile range, IVIg Intravenous immunoglobulin. Unless otherwise noted, values are shown as n (%)